Dr. Michael Morris, MD

Medical Oncology New York, NY Male
NPI: 1255302055
Total Payments
$100,755
2024 Payments
$19,442
Companies
26
Transactions
119
Medicare Patients
1,585
Medicare Billing
$205,452

Payment Breakdown by Category

Consulting$39,560 (39.3%)
Other$37,061 (36.8%)
Travel$10,219 (10.1%)
Research$9,960 (9.9%)
Food & Beverage$3,955 (3.9%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $39,560 25 39.3%
Honoraria $21,837 10 21.7%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,224 6 12.1%
Travel and Lodging $10,219 20 10.1%
Unspecified $9,960 8 9.9%
Food and Beverage $3,955 49 3.9%
Grant $3,000 1 3.0%

Payments by Type

General
$90,795
111 transactions
Research
$9,960
8 transactions

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $18,001 9 $0 (2024)
Blue Earth Diagnostics Limited $13,094 8 $0 (2023)
Daiichi Sankyo Inc. $7,762 7 $0 (2023)
Novartis Pharmaceuticals Corporation $7,640 4 $0 (2024)
Amgen Inc. $6,109 9 $0 (2024)
Bayer HealthCare Pharmaceuticals Inc. $6,063 9 $0 (2020)
PROGENICS PHARMACEUTICALS, INC. $5,660 9 $0 (2024)
TOLMAR Pharmaceuticals, Inc. $5,635 4 $0 (2017)
LANTHEUS MEDICAL IMAGING, INC. $5,028 3 $0 (2024)
Exelixis Inc. $3,989 3 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $19,442 18 LANTHEUS MEDICAL IMAGING, INC. ($5,028)
2023 $17,686 23 Blue Earth Diagnostics Limited ($6,500)
2022 $16,483 20 Daiichi Sankyo Inc. ($5,781)
2021 $18,023 10 PFIZER INC. ($10,450)
2020 $8,706 11 Advanced Accelerator Applications ($3,000)
2019 $3,011 13 Progenics Pharmaceuticals, Inc. ($1,925)
2018 $8,433 11 Bayer HealthCare Pharmaceuticals Inc. ($5,459)
2017 $8,971 13 TOLMAR Pharmaceuticals, Inc. ($5,635)

All Payment Transactions

119 individual payment records from CMS Open Payments — Page 1 of 5

Date Company Product Nature Form Amount Type
12/16/2024 PFIZER INC. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program In-kind items and services $3,700.00 General
11/28/2024 Novartis Pharma AG PLUVICTO (Drug), LOCAMETZ — In-kind items and services $1,275.59 Research
Study: CAAA617B12302 • Category: ONCOLOGY
10/10/2024 Novartis Pharma AG PLUVICTO (Drug), LOCAMETZ — In-kind items and services $237.67 Research
Study: CAAA617B12302 • Category: ONCOLOGY
10/08/2024 Amgen Inc. — Consulting Fee Cash or cash equivalent $1,372.00 General
09/15/2024 Novartis Pharma AG PLUVICTO (Drug), LOCAMETZ — In-kind items and services $508.59 Research
Study: CAAA617B12302 • Category: ONCOLOGY
09/14/2024 AstraZeneca Pharmaceuticals LP — Food and Beverage In-kind items and services $20.40 General
07/04/2024 Novartis Pharmaceuticals Corporation PLUVICTO (Drug) — Cash or cash equivalent $3,498.92 Research
Study: Research Publication/ Writing Support • Category: Oncology
07/02/2024 Janssen Research & Development, LLC — Consulting Fee Cash or cash equivalent $1,300.00 General
06/18/2024 LANTHEUS MEDICAL IMAGING, INC. — Consulting Fee Cash or cash equivalent $1,820.00 General
06/11/2024 LANTHEUS MEDICAL IMAGING, INC. — Food and Beverage In-kind items and services $22.55 General
06/01/2024 Novartis Pharmaceuticals Corporation — Food and Beverage In-kind items and services $135.00 General
05/31/2024 Janssen Research & Development, LLC — Food and Beverage In-kind items and services $127.90 General
05/08/2024 Janssen Research & Development, LLC — Consulting Fee Cash or cash equivalent $1,300.00 General
05/07/2024 Novartis Pharma AG PLUVICTO (Drug), LOCAMETZ — In-kind items and services $209.71 Research
Study: CAAA617B12302 • Category: ONCOLOGY
04/04/2024 LANTHEUS MEDICAL IMAGING, INC. — Consulting Fee Cash or cash equivalent $3,185.00 General
02/11/2024 Novartis Pharmaceuticals Corporation — — Cash or cash equivalent $453.74 Research
Study: PSMAfore
02/06/2024 Novartis Pharma AG PLUVICTO (Drug), LOCAMETZ — In-kind items and services $222.81 Research
Study: CAAA617B12302 • Category: ONCOLOGY
01/25/2024 PROGENICS PHARMACEUTICALS, INC. PYLARIFY (Drug) Food and Beverage In-kind items and services $52.11 General
Category: RADIOPHARMACEUTICAL
12/22/2023 Blue Earth Diagnostics Limited — Consulting Fee Cash or cash equivalent $2,000.00 General
11/13/2023 Exelixis Inc. CABOMETYX (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,980.00 General
Category: Oncology
10/27/2023 Amgen Inc. — Food and Beverage In-kind items and services $25.43 General
10/21/2023 Janssen Research & Development, LLC — Food and Beverage In-kind items and services $53.31 General
07/28/2023 E.R. Squibb & Sons, L.L.C. — Consulting Fee Cash or cash equivalent $655.00 General
07/12/2023 Amgen Inc. — Travel and Lodging Cash or cash equivalent $90.90 General
04/14/2023 E.R. Squibb & Sons, L.L.C. — Consulting Fee Cash or cash equivalent $1,624.40 General
123…5»

Research Studies & Clinical Trials

Study Name Company Amount Records
MS -1102132022 The Role of the Multidisciplinary Team in Providing PSMA-targeted Radioligand Therapy and Managing Adverse Events: A Review Novartis Pharmaceuticals Corporation $3,553 1
Research Publication/ Writing Support Novartis Pharmaceuticals Corporation $3,499 1
CAAA617B12302 Novartis Pharma AG $2,454 5
PSMAfore Novartis Pharmaceuticals Corporation $453.74 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 4 224 374 $187,805 $27,554
2022 6 439 768 $382,070 $58,810
2021 6 445 856 $443,335 $71,510
2020 10 477 794 $328,140 $47,578
Total Patients
1,585
Total Services
2,792
Medicare Billing
$205,452
Procedure Codes
26

All Medicare Procedures & Services

26 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 78 142 $77,390 $11,497 14.9%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 107 190 $71,250 $10,142 14.2%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2023 27 27 $28,215 $4,074 14.4%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 12 15 $10,950 $1,841 16.8%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 170 353 $192,385 $29,345 15.3%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 181 321 $120,375 $18,613 15.5%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2022 36 36 $37,620 $6,014 16.0%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 28 32 $23,680 $3,807 16.1%
99442 Telephone medical discussion with physician, 11-20 minutes Office 2022 12 14 $5,250 $659.10 12.6%
99212 Established patient office or other outpatient visit, 10-19 minutes Office 2022 12 12 $2,760 $372.14 13.5%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 186 464 $252,880 $41,726 16.5%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 153 234 $87,750 $12,721 14.5%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 39 39 $40,755 $6,389 15.7%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 11 51 $25,755 $4,852 18.8%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 23 31 $22,320 $3,693 16.5%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Office 2021 33 37 $13,875 $2,129 15.3%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 123 263 $136,760 $17,235 12.6%
99213 Established patient office or other outpatient visit, typically 15 minutes Office 2020 143 225 $79,875 $9,577 12.0%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 36 94 $46,530 $8,951 19.2%
99205 New patient office or other outpatient visit, typically 60 minutes Office 2020 28 28 $28,765 $3,928 13.7%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Office 2020 44 67 $10,135 $3,212 31.7%
99443 Physician telephone patient service, 21-30 minutes of medical discussion Office 2020 18 21 $4,620 $1,544 33.4%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 11 13 $8,970 $1,353 15.1%
99212 Established patient office or other outpatient visit, typically 10 minutes Office 2020 30 36 $7,740 $853.09 11.0%
99441 Physician telephone patient service, 5-10 minutes of medical discussion Office 2020 29 32 $3,545 $745.81 21.0%
12»

About Dr. Michael Morris, MD

Dr. Michael Morris, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255302055.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Morris, MD has received a total of $100,755 in payments from pharmaceutical and medical device companies, with $19,442 received in 2024. These payments were reported across 119 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($39,560).

As a Medicare-enrolled provider, Morris has provided services to 1,585 Medicare beneficiaries, totaling 2,792 services with total Medicare billing of $205,452. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.

Practice Information

  • Specialty Medical Oncology
  • Location New York, NY
  • Active Since 01/30/2006
  • Last Updated 04/06/2015
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1255302055

Products in Payments

  • Axumin (Drug) $6,594
  • PLUVICTO (Drug) $5,953
  • ELIGARD (Drug) $5,635
  • CABOMETYX (Drug) $3,960
  • PYLARIFY (Drug) $3,052
  • LUTATHERA (Drug) $3,000
  • ILLUCCIX (Drug) $2,803
  • 64Cu-PSMA-I&T (Drug) $2,713
  • TALZENNA (Drug) $2,187
  • XTANDI (Drug) $1,400
  • TECENTRIQ (Biological) $1,292
  • LYNPARZA (Drug) $1,028
  • NO PRODUCT DISCUSSED (Drug) $773.43
  • Xofigo (Drug) $604.32
  • ERLEADA (Drug) $273.94
  • Erleada (Drug) $249.83
  • ZYTIGA (Drug) $229.73
  • BALVERSA (Drug) $116.06
  • Cabometyx (Drug) $29.11
  • LUMAKRAS (Drug) $13.00

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in New York

Craig Thompson, Md, MD

Medical Oncology — Payments: $2.1M

Medical Oncology $2.1M

Andrew Seidman, Md, MD

Medical Oncology — Payments: $1.7M

Medical Oncology $1.7M

Dr. Joshua Richter, M.d, M.D

Medical Oncology — Payments: $1.6M

Medical Oncology $1.6M

Ghassan Abou-Alfa, Md, MD

Medical Oncology — Payments: $1.2M

Medical Oncology $1.2M

Edward Gelmann

Medical Oncology — Payments: $944,679

Medical Oncology $944,679

Miguel Perales, Md, MD

Medical Oncology — Payments: $759,555

Medical Oncology $759,555